Labcorp Appoints Victor Bulto to Board of Directors

Core Insights - Labcorp has appointed Victor Bulto, a seasoned pharmaceutical executive from Novartis, to its Board of Directors, effective December 1, 2025, highlighting the company's commitment to long-term growth through innovation and global healthcare leadership [1][3]. Company Overview - Labcorp is a global leader in innovative and comprehensive laboratory services, providing insights and advancing science to improve health and lives through diagnostics and drug development capabilities [3]. - The company employs nearly 70,000 individuals and serves clients in approximately 100 countries, supporting over 75% of new drugs and therapeutic products approved by the FDA in 2024, and performing more than 700 million tests annually [3]. Victor Bulto's Background - Victor Bulto has 25 years of experience in healthcare and currently oversees Novartis' U.S. business, which is a $20+ billion operation across four therapeutic areas: oncology, immunology, neuroscience, and cardiovascular-renal-metabolic [2]. - Bulto has a proven track record of leading large organizations and has shaped strategies that enable businesses to navigate regulatory and market pressures effectively [2]. Strategic Importance - Bulto's expertise in transformation and technology will be crucial for Labcorp as it aims to innovate through science and technology, enhancing value for customers and shareholders [3]. - His belief in Labcorp's mission and the potential for accelerating access to novel therapies aligns with the company's focus on patient-centered care and the future of healthcare [3].